| Prev Close | 137.60 |
| Open | 137.65 |
| Day Low/High | 136.72 / 137.78 |
| 52 Wk Low/High | 118.62 / 148.99 |
| Volume | 4.25M |
| Avg Volume | 9.28M |
Johnson & Johnson (JNJ)
137.20
0.40
0.29
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.66B |
| Market Cap | 371.22B |
| EPS | 5.70 |
| P/E Ratio | 24.60 |
| Div & Yield | 3.60 (2.58%) |
Jim Cramer: This Is a Rotation, Not a Recession
There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.
Why Pay a Premium for Estee Lauder?
EL's stock is up despite a guidance cut.
Jim Cramer: Could Turkey Prove to Be One More Buying Opportunity?
I always say that you should wait until you get an exogenous reason for stocks to come down and then you should pounce.
Buy Johnson & Johnson, Now Poised to Rally
Johnson & Johnson prices finally look ready to move up.
Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop
It is all about perception, and here are strong names to pick up on market weakness.
The 4 Cheapest 'Dividend Kings' to Buy Today
These stocks offer not only terrific histories of dividend increases, but are also trading at reasonable valuations.
Jim Cramer: How to Pick Stocks When the Market Is Flying Blind
This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.
Johnson & Johnson Is a Great Company, But Be Patient
Bulls see a $158 price target, but JNJ needs a rally to $135.28 for a breakout.
Kevin O'Leary's 'Wonderful' World of ETFs: 3 Great Ways to Follow the Shark
These funds from the Shark Tank star's O'Shares series focus on small-cap dividend names, internet giants and large-cap dividend U.S. dividend stocks.
Rewind: Why Jim Cramer Is Bullish on Johnson & Johnson Shares
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer is bullish on Johnson & Johnson shares.
Jim Cramer: A Pretty Wild Rally In Three Oppositional Groups
How can this be? Let's take a look at the camps so we can figure it out.
Jim Cramer on Johnson & Johnson's Pharmaceuticals Sales Growth
When investors review a drug company, pay close attention to its pharma performance, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.
Jim Cramer on Netflix, Goldman Sachs, Bank of America and Johnson & Johnson
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Tuesday's trending stocks from the floor of the New York Stock Exchange.
Highs (and Lows) of FANG Trading: Market Recon
My Netflix short was a big winner yesterday, but I am also long Amazon and Google, which were hit with pretty strong collateral damage.
Bank Leadership Is Covering Up Some Ugly Market Issues
This quarter Netflix is not going to be the star of earnings season.
Closing Bell: LIVE MARKETS BLOG
The major U.S. indices rose on Friday, closing out the week on a two-day winning streak.
Jim Cramer: This Market Isn't Done Going Higher
We aren't done moving higher even with the president ready to strike at a moment's notice against any of our allies.
Stocks Rise Modestly and 4 Other Stories to Watch Premarket Friday
Happy Friday the 13th! These are the stories moving the market ahead of today's opening bell.
REPLAY: Jim Cramer on Broadcom, CA, Johnson & Johnson, Citigroup & Canopy Growth
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Thursday's trending stocks from the floor of the New York Stock Exchange
Jim Cramer: This Market Is Not as Expensive as It Looks
The only way the market is "dangerously elevated" is if you believe that 2019 is going to be a horrendous year.
Crowning Achievement: Six Dividend Kings With 50+ Years of Rising Dividends
These 'recession-resistant' names have proven they can thrive in a variety of economic conditions and through changing technologies and sentiments.
The Charts and Indicators on Johnson & Johnson Are Still Mostly Bearish
Johnson & Johnson is among the companies that Jim Cramer has put on his new GLOOM index.
Jim Cramer: A GLUM Index For Gloomy Markets
Taking the measure of what's keeping the markets in the dumps.
Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs
The latest announcement from the U.S. Trade Representative's office is chilling reading for free trade supporters.
Latest Reasons to Avoid Alzheimer's Plays
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
Jim Cramer: Tech Can't Do it All Alone
Tech and retail gains aren't enough to lead markets to new highs.
Intermediate Trade: Johnson & Johnson
JNJ is one of the best of breed of the pharmaceuticals sector.
Knowledge Is Power in Buy & Sell Decisions
Johnson & Johnson is a premiere company, but the trick is knowing when to buy it.
How to Play the Long Side of Johnson & Johnson
Shares of the healthcare giant pick up a quant rating upgrade as the charts suggest gains ahead.
2 Trading Opportunities in Health Care
The potential of these setups on the weekly chart is rather good.
